Altimmune shares are trading higher after the company announced that it presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide at the American Diabetes Association's 84th Scientific Sessions.
Portfolio Pulse from Benzinga Newsdesk
Altimmune shares are trading higher following the presentation of data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide at the American Diabetes Association's 84th Scientific Sessions.
June 24, 2024 | 11:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Altimmune's stock price is rising due to the positive reception of data from its 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, presented at a major diabetes conference.
The positive data from the clinical trial and its presentation at a significant scientific conference are likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100